Neurocrine Biosciences NBIX Cash ratio
Cash ratio at other companies
Other financials
Where this comes from
Calculated from Neurocrine Biosciences’s reported figures.
Based on the most recent quarter.
The official record: Neurocrine Biosciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Neurocrine Biosciences's cash ratio.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Neurocrine Biosciences's cash ratio?
- Neurocrine Biosciences (NBIX) reported cash ratio of 0.3× in Q1 2026.
- How has Neurocrine Biosciences's cash ratio changed year-over-year?
- Neurocrine Biosciences's cash ratio decreased by 14.6% year-over-year, from 0.4× to 0.3×.
- What is the long-term trend for Neurocrine Biosciences's cash ratio?
- Over 4 years (2021 to 2025), Neurocrine Biosciences's cash ratio has grown at a -21.8% compound annual growth rate (CAGR), from 6.4× to 2.4×.
- What does cash ratio mean?
- How much of its short-term bills the company could pay with cash on hand right now.
- How do you interpret cash ratio?
- A buffer against stress, but persistently high cash ratios can indicate under-deployed capital. Interpret alongside the company's capital-allocation strategy.
- How does cash ratio compare across companies?
- Varies widely by business model and treasury policy; best read against the company's own history.